CY1108291T1 - Φαρμακοτεχνικες μορφες αντινεοπλαστικων μεσων, συγκεκριμενα τεμοζολομιδης, μεθοδοι παραγωγης και χρησης τους - Google Patents

Φαρμακοτεχνικες μορφες αντινεοπλαστικων μεσων, συγκεκριμενα τεμοζολομιδης, μεθοδοι παραγωγης και χρησης τους

Info

Publication number
CY1108291T1
CY1108291T1 CY20081100907T CY081100907T CY1108291T1 CY 1108291 T1 CY1108291 T1 CY 1108291T1 CY 20081100907 T CY20081100907 T CY 20081100907T CY 081100907 T CY081100907 T CY 081100907T CY 1108291 T1 CY1108291 T1 CY 1108291T1
Authority
CY
Cyprus
Prior art keywords
temoszolomides
medicines
plastic
production
methods
Prior art date
Application number
CY20081100907T
Other languages
English (en)
Inventor
Sydney Ugwu
Vinay Radhakrishnan
Peter M Ihnat
Leonore C Witchey-Lakshmanan
Usa
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27766051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1108291(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of CY1108291T1 publication Critical patent/CY1108291T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Στις διάφορες υλοποιήσεις της, αυτή η εφεύρεση αποκαλύπτει μια φαρμακοτεχνική μορφή η οποία περιέχει τουλάχιστον ένα αντινεοπλαστικό μέσον ή ένα φαρμακευτικώς αποδεκτό άλας του, και τουλάχιστον ένα μέσον επαύξησης της διαλυτοποίησης επαρκές για την ουσιαστική διάλυση του εν λόγω τουλάχιστον ενός αντινεοπλαστικού μέσου εντός ενός τουλάχιστον υδατικού αραιωτικού, όπου το εν λόγω μέσον επαύξησης της διαλυτοποίησης είναι ουρία, L-ιστιδίνη, L-θρεονίνη, L-ασπαραγίνη, L-σερίνη, L-γλουταμίνη ή μίγματα τους, μια λυοφιλοποιημένη σκόνη που περιέχει την εν λόγω φαρμακοτεχνική μορφή και είδη παραγωγής της.
CY20081100907T 2002-02-22 2008-08-25 Φαρμακοτεχνικες μορφες αντινεοπλαστικων μεσων, συγκεκριμενα τεμοζολομιδης, μεθοδοι παραγωγης και χρησης τους CY1108291T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35919802P 2002-02-22 2002-02-22
EP03709188A EP1478339B9 (en) 2002-02-22 2003-02-20 Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same

Publications (1)

Publication Number Publication Date
CY1108291T1 true CY1108291T1 (el) 2014-02-12

Family

ID=27766051

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100907T CY1108291T1 (el) 2002-02-22 2008-08-25 Φαρμακοτεχνικες μορφες αντινεοπλαστικων μεσων, συγκεκριμενα τεμοζολομιδης, μεθοδοι παραγωγης και χρησης τους

Country Status (24)

Country Link
US (9) US6987108B2 (el)
EP (1) EP1478339B9 (el)
JP (2) JP4077794B2 (el)
KR (1) KR100970528B1 (el)
CN (2) CN101172104B (el)
AR (3) AR038535A1 (el)
AT (1) ATE397440T1 (el)
AU (1) AU2003213142B2 (el)
BR (1) BRPI0307802B8 (el)
CA (2) CA2662899A1 (el)
CY (1) CY1108291T1 (el)
DE (1) DE60321450D1 (el)
DK (1) DK1478339T3 (el)
ES (1) ES2307905T3 (el)
HK (1) HK1066466A1 (el)
MX (1) MXPA04008133A (el)
NO (1) NO335045B1 (el)
NZ (1) NZ534378A (el)
PL (1) PL205936B1 (el)
PT (1) PT1478339E (el)
SG (1) SG161101A1 (el)
SI (1) SI1478339T1 (el)
WO (1) WO2003072082A1 (el)
ZA (1) ZA200406632B (el)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2307905T3 (es) * 2002-02-22 2008-12-01 Schering Corporation Formulaciones farmaceuticas de agentes antineoplasicos, en particular temozolomida, procedimientos de obtencion y de uso.
WO2005099666A2 (en) * 2004-04-01 2005-10-27 Teva Pharmaceutical Industries Ltd. Delayed release formulations of 6-mercaptopurine
US8188067B2 (en) 2004-04-01 2012-05-29 Teva Pharmaceutical Industries Ltd. Formulations of 6-mercaptopurine
CA2589484A1 (en) * 2004-12-02 2006-06-08 Schering Corporation Methods of using temozolomide formulation intrathecally in the treatment of cancers
CA2652926A1 (en) * 2006-05-26 2007-12-06 Bayer Healthcare Llc Drug combinations with substituted diaryl ureas for the treatment of cancer
JP5537946B2 (ja) 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬
US20100119592A1 (en) * 2006-12-08 2010-05-13 Bruce Michael Frankel Cytarabine for treatment of glioma
FR2910812B1 (fr) * 2006-12-29 2009-03-20 Pierre Fabre Medicament Sa Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante
JP2010526809A (ja) * 2007-05-08 2010-08-05 シェーリング コーポレイション テモゾロミドを含む静脈内処方物を用いる治療方法
US20080319039A1 (en) * 2007-06-25 2008-12-25 Jacqueline Rose Bersch Unit dosage forms of temozolomide
CN101467967B (zh) * 2007-12-29 2012-05-23 北京京卫燕康药物研究所有限公司 用于静脉和脑内注射的两元溶液型制剂
CN102007145A (zh) 2008-02-14 2011-04-06 百时美施贵宝公司 基于结合egfr的工程化蛋白质的靶向治疗剂
CN101559037B (zh) * 2008-04-16 2013-01-30 北京京卫燕康药物研究所有限公司 用于静脉和脑内注射的两元溶液型制剂
WO2009128955A1 (en) * 2008-04-18 2009-10-22 Teva Pharmaceutical Industries Ltd. Treatment of inflammatory bowel disease with 6-mercaptopurine
EP2291399B1 (en) 2008-05-22 2014-06-25 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
AR066943A1 (es) * 2008-06-10 2009-09-23 Eriochem Sa Una composicion farmaceutica de melfalano
CA2767331A1 (en) 2008-07-10 2010-01-14 Angion Biomedica Corp. Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
US8735457B2 (en) 2008-09-30 2014-05-27 Columbia Insurance Company Recycled polyethylene terephthalate compositions, fibers and articles produced therefrom, and methods for producing same
CA2883124C (en) 2008-09-30 2016-10-25 Shaw Industries Group, Inc. Recycled polyethylene terephthalate compositions, fibers and articles produced therefrom, and methods for producing same
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
EP2396000A1 (en) * 2009-02-11 2011-12-21 Bristol-Myers Squibb Company Combination vegfr2 therapy with temozolomide
WO2011036676A2 (en) 2009-09-23 2011-03-31 Ashwini Nangia Stable cocrystals of temozolomide
JP6023703B2 (ja) 2010-05-26 2016-11-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
CN101869551B (zh) * 2010-06-28 2012-04-18 江苏奥赛康药业股份有限公司 一种替莫唑胺冻干制剂
CN102342931B (zh) * 2010-07-29 2014-04-23 江苏恒瑞医药股份有限公司 替莫唑胺的可注射的胃肠外用药物制剂及其制备方法
CN101984968A (zh) * 2010-10-29 2011-03-16 北京润德康医药技术有限公司 抗肿瘤剂替莫唑胺的药物制剂制备方法
CN102659789B (zh) * 2011-04-27 2014-10-15 四川科瑞德凯华制药有限公司 一锅法制备替莫唑胺的方法及替莫唑胺的精制方法
LT3656393T (lt) * 2011-04-28 2022-12-12 Oncopeptides Ab Liofilizuoti citotoksinių dipeptidų preparatai
CN102178676B (zh) * 2011-04-29 2012-07-25 山东大学 一种治疗脑胶质瘤的药物组合物
CN102949351B (zh) * 2011-08-16 2015-05-13 上海汇伦生命科技有限公司 一种替莫唑胺冻干制剂的制备方法
CN102688202B (zh) * 2012-06-07 2013-08-14 北京莱瑞森医药科技有限公司 一种替莫唑胺冻干制剂
US8974811B2 (en) * 2013-03-14 2015-03-10 Hikma Pharmaceuticals Stabilized pharmaceutical formulations comprising antineoplastic compounds
CN104274412A (zh) * 2013-07-01 2015-01-14 北京恒瑞康达医药科技发展有限公司 一种含有替莫唑胺、其药学上可接受的盐或其他衍生物的药物制剂
CN103432085A (zh) * 2013-08-19 2013-12-11 南京海纳医药科技有限公司 一种含氨基酸增溶剂的替莫唑胺冻干制剂及其制备方法
PT2865391T (pt) * 2013-10-22 2017-12-22 Medac Ges Für Klinische Spezialpräparate Mbh Processo para a produção de uma composição farmacêutica liofilizada com um conteúdo de mitomicina c
WO2015193477A1 (en) * 2014-06-20 2015-12-23 Syddansk Universitet Auger electron therapy for glioblastoma
CN106794164A (zh) * 2014-08-14 2017-05-31 L.E.A.F.控股集团公司 脂质体包封的亲和性药物
CA2971868C (en) 2015-01-14 2023-04-04 Chiesi Farmaceutici S.P.A. Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
WO2017066619A1 (en) 2015-10-16 2017-04-20 Teva Pharmaceutical Industries Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
WO2017192088A1 (en) * 2016-05-02 2017-11-09 Double Bond Pharmaceuticals Ab Stable anti-neoplastic pharmaceutical composition comprising temozolomide and method of preparing the composition
JP6706988B2 (ja) * 2016-07-20 2020-06-10 日本化薬株式会社 ボルテゾミブを含有する医薬組成物
JOP20190204A1 (ar) * 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
CN107213123A (zh) * 2017-07-23 2017-09-29 南京正宽医药科技有限公司 一种注射用盐酸氨溴索及其制备方法
BE1025934B1 (fr) * 2018-01-12 2020-05-05 Hyloris Dev Sa Suspension pharmaceutique de méthylprednisolone
AU2020272036A1 (en) 2019-04-11 2021-11-04 Angion Biomedica Corp. Solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole
EP4065108A4 (en) * 2019-11-25 2023-12-20 The Johns Hopkins University TERAMEPROCOL AND TEMOZOLOMIDE FORMULATIONS AND THEIR USE IN STIMULATING HUMORAL IMMUNITY IN TUMORS
WO2021229442A1 (en) 2020-05-12 2021-11-18 Shorla Pharma Ltd Stable formulations of temozolomide for oral administration
WO2024071464A1 (ko) * 2022-09-27 2024-04-04 (주)바이오솔릭스 말레이트 금속염을 포함하는 항암용 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455256A (en) * 1981-05-05 1984-06-19 The Regents Of The University Of California Bone morphogenetic protein
US5260291A (en) * 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US5731304A (en) * 1982-08-23 1998-03-24 Cancer Research Campaign Technology Potentiation of temozolomide in human tumour cells
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
GB8426672D0 (en) 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
US5204335A (en) 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
JPS63313721A (ja) * 1987-06-17 1988-12-21 Teisan Seiyaku Kk 速溶性の注射用組成物
SU1479049A1 (ru) * 1987-07-01 1989-05-15 Научно-производственное объединение "Биолар" Способ получени концентрата водорастворимых фосфолипидов
US5066647A (en) 1989-04-20 1991-11-19 Erbamont, Inc. Cyclophosphamide - alanine lyophilizates
JP2977236B2 (ja) * 1990-07-20 1999-11-15 株式会社東芝 音声合成装置
US5268368A (en) * 1991-05-17 1993-12-07 Erbamont, Inc. Cyclophosphamide--amino acid lyophilizates
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
MX9400434A (es) * 1993-01-14 1994-07-29 Cancer Res Campaign Tech Potenciamiento de temozolomida en celulas de tumores humanos.
DE4331147A1 (de) * 1993-09-14 1995-03-16 Nycomed Arzneimittel Gmbh Intravenös verabreichbare, wäßrige Lösung
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
ATE297761T1 (de) 1998-03-26 2005-07-15 Schering Corp Zubereitungen zur stabilisierung von peg- interferon alpha konjugaten
US6251886B1 (en) * 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US5972912A (en) 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
JP2003519150A (ja) * 1999-12-24 2003-06-17 バイエル アクチェンゲゼルシャフト 新規なイミダゾ［１，３，５］トリアジノン類及びその使用
ES2307905T3 (es) * 2002-02-22 2008-12-01 Schering Corporation Formulaciones farmaceuticas de agentes antineoplasicos, en particular temozolomida, procedimientos de obtencion y de uso.
WO2006052976A2 (en) * 2004-11-09 2006-05-18 Schering Corporation Improved dosing regimen of temozolomide for treating cancer based on the patient’s mgmt level

Also Published As

Publication number Publication date
US7786118B2 (en) 2010-08-31
JP4785816B2 (ja) 2011-10-05
EP1478339B9 (en) 2009-08-19
ATE397440T1 (de) 2008-06-15
US20040043001A1 (en) 2004-03-04
AU2003213142A1 (en) 2003-09-09
BRPI0307802B1 (pt) 2018-11-27
AU2003213142B2 (en) 2005-11-10
AR064722A2 (es) 2009-04-22
US20160082005A1 (en) 2016-03-24
BR0307802A (pt) 2004-12-21
US20120053219A1 (en) 2012-03-01
PL372319A1 (en) 2005-07-11
US20090176852A1 (en) 2009-07-09
NO335045B1 (no) 2014-09-01
WO2003072082A1 (en) 2003-09-04
HK1066466A1 (en) 2005-03-24
SG161101A1 (en) 2010-05-27
CA2476494A1 (en) 2003-09-04
US6987108B2 (en) 2006-01-17
CN1635871A (zh) 2005-07-06
US7674790B2 (en) 2010-03-09
NO20043961L (no) 2004-09-21
MXPA04008133A (es) 2004-11-26
SI1478339T1 (sl) 2008-10-31
US20140088166A1 (en) 2014-03-27
CN101172104B (zh) 2013-04-03
EP1478339B1 (en) 2008-06-04
DK1478339T3 (da) 2008-08-25
KR100970528B1 (ko) 2010-07-16
DE60321450D1 (de) 2008-07-17
US8076335B2 (en) 2011-12-13
EP1478339A1 (en) 2004-11-24
US20060122163A1 (en) 2006-06-08
NZ534378A (en) 2006-10-27
CN101172104A (zh) 2008-05-07
AR038535A1 (es) 2005-01-19
BRPI0307802B8 (pt) 2021-05-25
PL205936B1 (pl) 2010-06-30
JP2005518434A (ja) 2005-06-23
KR20040085196A (ko) 2004-10-07
JP2008031186A (ja) 2008-02-14
CA2476494C (en) 2010-04-27
US20100331382A1 (en) 2010-12-30
JP4077794B2 (ja) 2008-04-23
ES2307905T3 (es) 2008-12-01
CN100346784C (zh) 2007-11-07
AR084868A2 (es) 2013-07-10
CA2662899A1 (en) 2003-09-04
US8623868B2 (en) 2014-01-07
US20180078546A1 (en) 2018-03-22
US20190336495A1 (en) 2019-11-07
ZA200406632B (en) 2005-11-30
PT1478339E (pt) 2008-09-05

Similar Documents

Publication Publication Date Title
CY1108291T1 (el) Φαρμακοτεχνικες μορφες αντινεοπλαστικων μεσων, συγκεκριμενα τεμοζολομιδης, μεθοδοι παραγωγης και χρησης τους
CY1108408T1 (el) Παραγωγα διαζεπινοϊνδολιου ως αναστολεις κινασης
EA200401318A1 (ru) Производные хинолинона
AR111572A2 (es) Formas farmacéuticas que contienen vardenafilo
CY1112084T1 (el) Παραγωγα 5-φαινυλθειαζολης και χρηση ως αναστολεις της κινασης ρi3
CY1110332T1 (el) Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους
CY1116693T1 (el) Συνδυασμος αζελαστινης και κυκλεσονιδης
CY1111039T1 (el) Παραγωγα 4-ανιλινο κιναζολινης ως αντιπολλαπλασιαστικοι παραγοντες
CY1108656T1 (el) Παραγωγα της πυριμιδινο-2,4-διονης ως ανταγωνιστες των υποδοχεων της εκλυουσας γοναδοτροπινες ορμονης
UY28736A1 (es) Derivados de quinazolina
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
PT1155692E (pt) Utilizacao de paclitaxel estabilizado com albumina para a preparacao de um farmaco para o tratamento de tumores solidos e o farmaco assim obtido
DE60217674D1 (de) Derivate heterocyclischer verbindungen und arzneimittel
CY1108254T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
CY1109119T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη
CY1119580T1 (el) Νεα φαρμακα σκευασματα χρησιμα στη θεραπευτικη αγωγη της αϋπνιας
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
ATE426635T1 (de) Arzneimittelverabreichung
CY1110449T1 (el) Συνδυασμος δοκεταξελης και φλαβοπιριδinολης
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
CL2004000877A1 (es) Combinacion farmaceutica que comprende 8a) melatonina y agonistas de la melatonina, y nicotina y agonistas receptores de nicotina; kit farmaceutico, y; uso en el tratamiento de insomnio, dificultades cognitivas y dificultades de memoria; kit farmaceu
ITRM20030394A1 (it) Uso dell'indometacina e derivati come farmaci antivirali e relative composizioni farmaceutiche.
NO20075508L (no) Stannsoporfinpreparater og administrering
ATE491450T1 (de) Behandlung proliferativer erkrankungen mit epothilon-derivaten und bestrahlung